Author:
Primrose Naomi,Johnston Emma
Abstract
Inflammatory bowel diseases commonly present in young adulthood and it is estimated that up to one in 200 pregnant women have IBD. Key factors for successful pregnancy outcome are disease remission at the time of conception and optimal disease control during pregnancy, with active disease increasing the risk of adverse effects for both mother and baby. This article forms part of a series on prescribing for pregnancy and discusses the impact of IBD on pregnancy and the influence pregnancy may have on IBD. It highlights the importance of prepregnancy care and collaborative working between obstetric and gastroenterology specialties as well as focusing on prescribing before, during and after pregnancy, exploring treatment options for IBD which are evolving rapidly as new immunosuppressive agents emerge.
Subject
Pharmacology (medical),General Medicine
Reference52 articles.
1. Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000-2018;King;Aliment Pharmacol Ther,2020
2. Inflammatory Bowel Disease in Pregnancy
3. The Second European Evidenced-Based Consensus on Reproduction and Pregnancy in Inflammatory Bowel Disease
4. Selinger CP , Carey N , Cassere S , et al . Standards for the provision of antenatal care for patients with inflammatory bowel disease: A BSG PS endorsed by the British Maternal and Fetal Medicine Society [online], 2019. Available: https://www.bsg.org.uk/clinical-resource/standards-for-the-provision-of-antenatal-care-for-patients-with-ibd-a-bsg-ps-endorsed-by-the-british-maternal-and-fetal-medicine-society/ [Accessed 16 Dec 2021].
5. Prescribing for pregnancy: general prepregnancy care